Overview

Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis

Status:
Unknown status
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
To prove the organ-reversing potential of thalidomide for amyloidosis with cardiac involvement
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
CW pharmaceutical company
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Thalidomide